Methylation of helicase-like transcription factor in serum of patients with colorectal cancer is an independent predictor of disease recurrence

Herbst, Andreas; Wallner, Maike; Rahmig, Konstanze; Stieber, P.; Crispin, Alexander; Lamerz, R.; Kolligs, Frank T.

doi:10.1097/meg.0b013e328318ecf2

Cited by 68 publications

(64 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, the methylation of this gene can serve as an independent biomarker for the identification of CRC with an increased risk of death. These results indicate that detection of HLTF methylation in the blood of CRC patients has the potential as a pretherapeutic predictor of patient outcome [32] . Deafness, autosomal dominant 5 (DFNA5) is another candidate biomarker for the noninvasive screening and monitoring of CRC.…”

Section: Mirna Biomarkers Mirna and Cancermentioning

confidence: 73%

Advances in epigenetic biomarker research in colorectal cancer

Kuang

2014

WJG

View full text Add to dashboard Cite

Colorectal cancer (CRC) causes approximately 600000 deaths annually and is the third leading cause of cancer mortality worldwide. Despite significant advancements in treatment options, CRC patient survival is still poor owing to a lack of effective tools for early diagnosis and a limited capacity for optimal therapeutic decision making. Since there exists a need to find new biomarkers to improve diagnosis of CRC, the research on epigenetic biomarkers for molecular diagnostics encourages the translation of this field from the bench to clinical practice. Epigenetic alterations are thought to hold great promise as tumor biomarkers. In this review, we will primarily focus on recent advances in the study of epigenetic biomarkers for colorectal cancer and discuss epigenetic biomarkers, including DNA methylation, microRNA expression and histone modification, in cancer tissue, stool, plasma, serum, cell lines and xenografts. These studies have improved the chances that epigenetic biomarkers will find a place in the clinical practices of screening, early diagnosis, prognosis, therapy choice and recurrence surveillance for CRC patients. However, these studies have typically been small in size, and evaluation at a larger scale of well-controlled randomized clinical trials is the next step that is necessary to increase the quality of epigenetic biomarkers and ensure their widespread clinical use.

show abstract

Section: Mirna Biomarkers Mirna and Cancermentioning

confidence: 73%

Advances in epigenetic biomarker research in colorectal cancer

Kuang

2014

WJG

View full text Add to dashboard Cite

show abstract

“…HLTF promoter methylation is rarely observed in normal colon tissue (3.0-10.2 %). However, it is increased in colon adenoma (25.7-68.5 %) [13,56] and remains stable or slightly increased in invasive carcinomas (34.3-41.4 %), independently of tumor stage [13,[55][56][57][58][59][60][61][62][63][64][65][66][67][68][69][70] ( Table 3). HLTF promoter hypermethylation was analyzed in association with the methylation of other genes.…”

Section: Hltf Silencing Through Promoter Hypermethylationmentioning

confidence: 99%

The helicase-like transcription factor (HLTF) in cancer: loss of function or oncomorphic conversion of a tumor suppressor?

Dhont

Mascaux

Belayew

2015

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

The Helicase-like Transcription Factor (HLTF) belongs to the SWI/SNF family of proteins involved in chromatin remodeling. In addition to its role in gene transcription, HLTF has been implicated in DNA repair, which suggests that this protein acts as a tumor suppressor. Accumulating evidence indicates that HLTF expression is altered in various cancers via two mechanisms: gene silencing through promoter hypermethylation or alternative mRNA splicing, which leads to the expression of truncated proteins that lack DNA repair domains. In either case, the alteration of HLTF expression in cancer has a poor prognosis. In this review, we gathered published clinical and molecular data on HLTF. Our purposes are (a) to address whether HLTF alterations could be considered as cancer drivers or passengers and (b) to determine whether its different functions (transcription or DNA repair) could be diverted in clonal selection during cancer progression.

show abstract

“…Several studies also suggest that methylated DNA released in the circulation could be used as a prognostic marker for early tumor detection. The presence of aberrantly methylated genes such as SEPT9, HLTF and HPP1 DNA in plasma is highly correlated with the occurrence of colorectal cancer and tumor size, stage, grade and metastatic disease, respectively (deVos et al, 2009;Herbst et al, 2009;Lange et al, 2012;Summers, et al, 2013).…”

Section: Mgmt-b Gene Promoter Hypermethylation In Patients With Inflamentioning

confidence: 99%

MGMT-B Gene Promoter Hypermethylation in Patients with Inflammatory Bowel Disease - A Novel Finding

Mokarram

Kavousipour²,

Sarabi³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Methylation of helicase-like transcription factor in serum of patients with colorectal cancer is an independent predictor of disease recurrence

Abstract: Here, we show for the first time that a DNA methylation-based surrogate marker can serve as a predictor of disease recurrence in colorectal cancer.

Cited by 68 publications

References 23 publications

Advances in epigenetic biomarker research in colorectal cancer

Advances in epigenetic biomarker research in colorectal cancer

The helicase-like transcription factor (HLTF) in cancer: loss of function or oncomorphic conversion of a tumor suppressor?

MGMT-B Gene Promoter Hypermethylation in Patients with Inflammatory Bowel Disease - A Novel Finding

Contact Info

Product

Resources

About